Skip to main content

Table 2 Effect sizes of sub-dimensions of QoL that could be pooled by meta-analyses (positive [negative] values in functioning [symptom] dimensions indicate improvement for VAE vs. control)

From: Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis

Dimension

Included studies

# of patients

SMD

95% CI

p value

Physical functioning

[26, 30, 40, 42, 47,48,49, 46, 50, 52]

1116

0,65

−0,11-1,41

0,09

Role functioning

[26, 30, 40, 42, 47,48,49, 46, 50, 52]

1116

0,63

0,05-1,22

0,04

Emotional functioning

[26, 30, 40, 42, 47,48,49, 46, 50, 52]

1116

0,52

−0,10 − 1,13

0,1

Cognitive functioning

[26, 30, 40, 42, 48, 49, 47, 50, 52]

779

0,46

− 0,21 − 1,13

0,18

Social functioning

[26, 30, 40, 42, 48, 49, 47, 50, 52]

779

0,62

0,22-1,03

0,002

Fatigue

[26, 30, 40, 42, 48, 49, 47, 50, 52]

779

−0,79

−1,66 − 0,08

0,08

Nausea/Vomitting

[26, 30, 40, 42, 46,47,48,49, 45, 50, 52]

1247

− 0,55

-1-(− 0,1)

0,02

Pain

[26, 30, 40, 42, 47,48,49, 46, 50, 52]

1116

− 0,86

− 1,54-(− 0,18)

0,01

Dyspnea

[26, 30, 40, 42, 48, 49, 47, 50, 52]

779

−0,37

-0,65-(− 0,09)

0,009

Insomnia

[26, 30, 40, 42, 46,47,48,49, 45, 50, 52]

1247

-0,54

−1,23 − 0,14

0,12

Appetite loss

[26, 30, 40, 42, 46,47,48,49, 45, 50, 52]

1247

−0,62

-1,29 − 0,05

0,07

Constipation

[26, 30, 40, 42, 48, 49, 47, 50, 52]

779

− 0,14

−0,41-0,13

0,31

Diarrhea

[26, 30, 40, 42, 48, 49, 47, 50, 52]

779

-0,43

-0,86-0,01

0,05

Financial difficulties

[26, 30, 40, 48, 49, 47, 50, 52]

713

-0,69

−1,21-(− 0,16)

0,01